IShares Genomics Financials
| IDNA Etf | USD 24.08 0.53 2.15% |
Net Expense Ratio 0.0047 |
IShares |
The data published in IShares Genomics' official financial statements typically reflect IShares Genomics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving IShares Genomics' quantitative information. For example, before you start analyzing numbers published by IShares accountants, it's essential to understand IShares Genomics' liquidity, profitability, and earnings quality within the context of the iShares space in which it operates.
Please note, the presentation of IShares Genomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, IShares Genomics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of IShares Genomics' management manipulating its earnings.
IShares Genomics Etf Summary
IShares Genomics competes with Vanguard Consumer, Vanguard Financials, Vanguard Information, Vanguard Consumer, and Vanguard Utilities. The fund generally will invest at least 80 percent of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Genomics Immunology is traded on NYSEARCA Exchange in the United States.IShares Genomics Key Financial Ratios
IShares Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining IShares Genomics's current stock value. Our valuation model uses many indicators to compare IShares Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IShares Genomics competition to find correlations between indicators driving IShares Genomics's intrinsic value. More Info.iShares Genomics Immunology is considered the top ETF in beta as compared to similar ETFs. It also is considered the top ETF in one year return as compared to similar ETFs reporting about 18.52 of One Year Return per Beta. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IShares Genomics' earnings, one of the primary drivers of an investment's value.iShares Genomics Imm Systematic Risk
IShares Genomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. IShares Genomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on iShares Genomics Imm correlated with the market. If Beta is less than 0 IShares Genomics generally moves in the opposite direction as compared to the market. If IShares Genomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one iShares Genomics Imm is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of IShares Genomics is generally in the same direction as the market. If Beta > 1 IShares Genomics moves generally in the same direction as, but more than the movement of the benchmark.
About IShares Genomics Financials
What exactly are IShares Genomics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include IShares Genomics' income statement, its balance sheet, and the statement of cash flows. Potential IShares Genomics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although IShares Genomics investors may use each financial statement separately, they are all related. The changes in IShares Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on IShares Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.IShares Genomics Thematic Clasifications
iShares Genomics Immunology is part of several thematic ideas from Theme ETFs to Strategy ETFs. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasIShares Genomics December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of IShares Genomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of iShares Genomics Immunology. We use our internally-developed statistical techniques to arrive at the intrinsic value of iShares Genomics Immunology based on widely used predictive technical indicators. In general, we focus on analyzing IShares Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build IShares Genomics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 6.2 | |||
| Value At Risk | (2.24) | |||
| Potential Upside | 1.74 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Genomics Immunology. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.